Lutetium (177Lu) Chloride Billev
Radiopharmaceutical Precursor for Targeted Radionuclide Therapy
Lutetium (177Lu) chloride Billev is a radiopharmaceutical precursor containing the radioactive isotope lutetium-177. It is not administered directly to patients but is used in nuclear medicine facilities to radiolabel carrier molecules such as peptides and antibodies. These radiolabeled compounds are then used in targeted radionuclide therapy for cancers including neuroendocrine tumors and metastatic prostate cancer. The product must be handled exclusively by qualified professionals in authorized facilities.
Quick Facts
Key Takeaways
- Lutetium (177Lu) chloride Billev is a radiopharmaceutical precursor, not a finished medicine for direct patient administration.
- It is used to radiolabel carrier molecules for targeted radionuclide therapy in cancers such as neuroendocrine tumors and prostate cancer.
- Lutetium-177 emits therapeutic beta particles and imaging gamma photons, enabling both treatment and monitoring in a single isotope.
- The product is classified as radioactive material and must be handled exclusively in authorized nuclear medicine facilities by qualified personnel.
- When used in final radiolabeled therapies, lutetium-177 based treatments have demonstrated significant improvements in progression-free survival in clinical trials.
What Is Lutetium (177Lu) Chloride Billev and What Is It Used For?
Lutetium (177Lu) chloride Billev contains the radioactive isotope lutetium-177 dissolved in a hydrochloric acid solution. Lutetium-177 is produced through neutron irradiation and is classified as a no-carrier-added (n.c.a.) radionuclide, meaning it has very high specific activity. This high specific activity is essential for achieving optimal radiolabeling efficiency when preparing therapeutic radiopharmaceuticals.
The product is designed exclusively for use as a radiopharmaceutical precursor. In nuclear medicine, a precursor is a starting material that is combined with a carrier molecule (such as a peptide, antibody, or small molecule) through a chemical process called radiolabeling. The resulting radiolabeled compound becomes the final radiopharmaceutical that is administered to patients. Lutetium (177Lu) chloride Billev itself is never given directly to patients.
The most important clinical applications of lutetium-177 based radiopharmaceuticals include peptide receptor radionuclide therapy (PRRT) for somatostatin receptor-positive neuroendocrine tumors, and radioligand therapy (RLT) for prostate-specific membrane antigen (PSMA)-expressing metastatic castration-resistant prostate cancer. In PRRT, lutetium-177 is attached to DOTATATE, a somatostatin analog that binds to somatostatin receptors overexpressed on neuroendocrine tumor cells. In RLT, lutetium-177 is attached to PSMA-617, a small molecule that binds to PSMA on prostate cancer cells.
How Does Lutetium-177 Work as a Therapeutic Radionuclide?
Lutetium-177 is classified as a medium-energy beta-emitting radionuclide. It decays by beta-minus emission, producing beta particles with a maximum energy of 498 keV and a mean energy of 134 keV. These beta particles have a maximum tissue penetration range of approximately 2 millimeters, which is sufficient to irradiate tumor cells and their immediate microenvironment while minimizing damage to distant healthy tissues.
In addition to beta particles, lutetium-177 also emits low-energy gamma photons at 208 keV (11% abundance) and 113 keV (6.4% abundance). These gamma emissions are particularly valuable because they allow post-therapy imaging using single-photon emission computed tomography (SPECT). This dual capability of lutetium-177 makes it an ideal theranostic radionuclide, enabling both therapy and diagnostic imaging with the same isotope. Clinicians can verify that the radiopharmaceutical has reached the target tumors and perform dosimetry calculations to optimize treatment planning.
The physical half-life of lutetium-177 is approximately 6.647 days, which is well-suited for targeted radionuclide therapy. This half-life provides sufficient time for the radiolabeled compound to accumulate in tumor tissue and deliver a therapeutic radiation dose, while also being short enough that radiation exposure to the patient diminishes relatively quickly after treatment.
The term "theranostics" refers to the combination of therapy and diagnostics. Lutetium-177 is considered an ideal theranostic radionuclide because its beta emissions provide therapeutic radiation to tumors while its gamma emissions allow imaging for treatment verification and dosimetry. This approach represents one of the most significant advances in personalized cancer medicine.
What Should You Know Before Using Lutetium (177Lu) Chloride Billev?
Since Lutetium (177Lu) chloride Billev is a radiopharmaceutical precursor and not a direct patient medication, the safety considerations primarily concern the handling, quality assurance, and radiolabeling process in the nuclear medicine facility. However, understanding these requirements is essential for patients and caregivers to appreciate the safety framework surrounding lutetium-177 based therapies.
Facility and Personnel Requirements
The receipt, storage, handling, and use of Lutetium (177Lu) chloride Billev is restricted to facilities that hold the appropriate governmental authorization and regulatory licenses for working with unsealed radioactive sources. These facilities must have designated radioactive material handling areas (hot labs) equipped with appropriate shielding, ventilation, and contamination monitoring systems.
Personnel involved in the preparation and handling of the product must be trained in radiation protection principles and hold relevant qualifications as nuclear medicine physicians, radiopharmacists, or nuclear medicine technologists. All procedures must comply with national regulations implementing the International Atomic Energy Agency (IAEA) Basic Safety Standards and the European Council Directive 2013/59/Euratom on basic safety standards for protection against ionizing radiation.
Quality Control Before Radiolabeling
Before using Lutetium (177Lu) chloride Billev for radiolabeling, quality control tests should be performed according to the radiopharmacy's standard operating procedures and the manufacturer's instructions. These checks typically include verification of radionuclidic purity, radiochemical purity, pH, and specific activity. The product should meet the specifications outlined in the relevant pharmacopoeial monograph and the marketing authorization.
Radionuclidic purity is particularly important because the presence of long-lived radioactive impurities (such as lutetium-177m, with a half-life of approximately 160 days) could increase long-term radiation exposure to patients receiving the final radiolabeled product. The no-carrier-added production method used for Lutetium (177Lu) chloride Billev helps to minimize the content of lutetium-177m compared to carrier-added alternatives.
Contraindications for Final Radiolabeled Products
While the precursor itself does not have patient-specific contraindications (since it is not administered to patients), the final radiolabeled products prepared using Lutetium (177Lu) chloride Billev do have contraindications that must be evaluated by the treating physician. These vary depending on the specific carrier molecule used:
- Pregnancy and breastfeeding: Radionuclide therapy with lutetium-177 based products is contraindicated during pregnancy due to the risk of radiation exposure to the fetus. Women of childbearing potential must use effective contraception during and for a specified period after treatment. Breastfeeding must be discontinued before treatment.
- Severe renal impairment: Patients with severely compromised kidney function may be at increased risk of nephrotoxicity from certain lutetium-177 based therapies, particularly when amino acid co-infusion protocols are used for renal protection.
- Severe bone marrow suppression: Pre-existing severe cytopenias (low blood cell counts) may be a contraindication, as lutetium-177 based therapies can cause bone marrow suppression.
- Hypersensitivity: Known hypersensitivity to the active substance or any excipients of the final radiolabeled product.
Radiation Protection Considerations
All handling of Lutetium (177Lu) chloride Billev must follow the ALARA principle (As Low As Reasonably Achievable), which is the fundamental tenet of radiation protection. This includes using appropriate lead or tungsten shielding, minimizing time spent in proximity to the radioactive material, maximizing distance from the source, and using remote handling tools where possible.
Lutetium (177Lu) chloride Billev is a radioactive material. Improper handling can result in radiation exposure. All procedures must be performed in accordance with radiation protection regulations by authorized personnel in licensed facilities. Appropriate personal dosimetry monitoring must be worn at all times during handling.
How Does Lutetium-177 Therapy Interact with Other Drugs?
Since Lutetium (177Lu) chloride Billev is a precursor and not directly administered to patients, drug interactions are relevant to the final radiolabeled products prepared from it. The interaction profile depends on the specific carrier molecule. The following table summarizes the most clinically important interactions associated with lutetium-177 based therapies.
| Drug / Drug Class | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| Long-acting somatostatin analogs (octreotide LAR, lanreotide) | Competitive receptor binding | Major - may reduce tumor uptake of Lu-177 DOTATATE | Discontinue long-acting analogs 4-6 weeks before PRRT; short-acting octreotide may continue until 24h before |
| Nephrotoxic drugs (aminoglycosides, cisplatin, NSAIDs) | Additive renal toxicity | Major - increased risk of kidney damage | Avoid concurrent use; ensure adequate renal function before treatment |
| Myelosuppressive chemotherapy (capecitabine, temozolomide) | Additive bone marrow suppression | Major - increased risk of severe cytopenias | Use with caution; monitor blood counts closely; combination protocols require specialized experience |
| Corticosteroids (dexamethasone, prednisolone) | May affect tumor receptor expression | Moderate - potential reduction in somatostatin receptor density | Review necessity; discuss with nuclear medicine team |
| Antiemetics (ondansetron, granisetron) | Supportive medication | Beneficial - used to manage treatment-related nausea | Routinely administered before and after treatment |
| Amino acid solutions (lysine, arginine) | Renal protective agent | Beneficial - reduces kidney radiation dose by 20-40% | Co-infusion recommended during PRRT to reduce nephrotoxicity |
Major Interactions
The most clinically significant interaction for Lu-177 DOTATATE therapy (PRRT) is with long-acting somatostatin analogs such as octreotide LAR and lanreotide. These agents compete with the radiolabeled DOTATATE for binding to somatostatin receptors on tumor cells. If present at the time of PRRT, long-acting analogs can significantly reduce tumor uptake of the radiopharmaceutical, potentially compromising treatment efficacy. International guidelines (ENETS, EANM) recommend discontinuing long-acting somatostatin analogs at least 4 to 6 weeks before PRRT treatment, while short-acting subcutaneous octreotide can be continued until 24 hours before the procedure.
For Lu-177 PSMA-617 therapy, interactions with other treatments affecting PSMA expression are relevant. Some evidence suggests that certain hormonal therapies (such as enzalutamide) may upregulate PSMA expression, potentially enhancing tumor uptake. However, this remains an area of active research and clinical protocols should be followed as directed by the treating physician.
Minor Interactions
Several medications commonly used by cancer patients may have minor interactions with lutetium-177 based therapies. Proton pump inhibitors (PPIs) and H2 receptor antagonists do not have significant direct interactions but may affect the absorption of supportive oral medications. Similarly, anticoagulants and antiplatelet agents do not interact with the radiopharmaceutical itself but should be monitored due to the potential for treatment-related thrombocytopenia that could increase bleeding risk.
Patients should provide a complete medication list to their nuclear medicine team before each treatment cycle, including over-the-counter medications, herbal supplements, and vitamins. Some supplements containing metals or chelating agents could theoretically interfere with the radiolabeling process if the final product is prepared extemporaneously, although this is primarily a concern for the radiopharmacist rather than the patient.
What Is the Correct Dosage of Lutetium (177Lu) Chloride Billev?
As a radiopharmaceutical precursor, Lutetium (177Lu) chloride Billev does not have a patient dosage in the traditional sense. The quantity used for each radiolabeling preparation depends on the target activity of the final product, the labeling efficiency, the calibration date of the precursor, and the scheduled administration time. Radiopharmacists calculate the required starting activity of lutetium-177 chloride based on radioactive decay tables and the specific requirements of the radiolabeling protocol.
Typical Activity Levels for Final Products
While the precursor dosage varies, the following information about typical therapeutic activities of the most common final radiolabeled products provides important context for understanding how Lutetium (177Lu) chloride Billev is used in clinical practice.
| Parameter | Lu-177 DOTATATE (PRRT) | Lu-177 PSMA-617 (RLT) |
|---|---|---|
| Activity per cycle | 7.4 GBq (200 mCi) | 7.4 GBq (200 mCi) |
| Number of cycles | 4 cycles | Up to 6 cycles |
| Interval between cycles | 8 weeks | 6 weeks |
| Cumulative activity | 29.6 GBq (800 mCi) | Up to 44.4 GBq (1200 mCi) |
| Administration route | Intravenous infusion (30 min) | Intravenous infusion (30 min) |
| Primary indication | GEP-NETs (somatostatin receptor-positive) | mCRPC (PSMA-positive) |
Dosing Considerations for Specific Populations
Adults
Standard dosing regimens as described above are used for adult patients. The treating physician may adjust the activity based on individual patient factors including body weight, tumor burden, kidney function, and bone marrow reserve. Personalized dosimetry-based dosing is increasingly being explored to optimize the therapeutic ratio.
Children and Adolescents
The use of lutetium-177 based therapies in pediatric patients is limited and typically reserved for compassionate use or clinical trials. Activity adjustments are made based on body weight or body surface area, and dosimetry-guided approaches are strongly recommended in this population. The European Association of Nuclear Medicine (EANM) provides specific dosimetry guidance for pediatric nuclear medicine applications.
Elderly Patients
No routine dose adjustment is required based on age alone. However, elderly patients may have reduced renal function and bone marrow reserve, which should be assessed before each treatment cycle. Baseline and interval kidney function tests (GFR or creatinine clearance) and complete blood counts are mandatory.
Renal Impairment
Patients with mild to moderate renal impairment may receive treatment with appropriate monitoring. For PRRT, amino acid co-infusion is used to reduce renal radiation absorbed dose. Patients with severe renal impairment (GFR less than 30 mL/min) may require individual dosimetry-based activity reduction or may be excluded from treatment depending on the specific clinical protocol.
Missed Dose and Overdose
Missed dose: Since lutetium-177 based therapies are administered in a controlled hospital setting at scheduled intervals, missed doses in the traditional sense do not apply. If a treatment cycle is delayed due to insufficient bone marrow recovery or other clinical reasons, the nuclear medicine physician will reschedule the treatment when the patient meets the retreatment criteria. Delays between cycles do not require adjustment of the individual cycle activity.
Overdose: Accidental overdose with radioactive material is a serious medical event. In the unlikely event of an overdose with the final radiolabeled product, management is supportive and guided by radiation safety protocols. Increased hydration and frequent voiding are encouraged to promote renal excretion. The radiation absorbed dose to organs at risk should be estimated through dosimetry. Complete blood counts should be monitored frequently due to the risk of severe bone marrow suppression. There is no specific antidote for lutetium-177 overdose.
What Are the Side Effects of Lutetium-177 Based Therapies?
Since Lutetium (177Lu) chloride Billev is a precursor that is not administered directly to patients, the side effects described here relate to the final radiolabeled products prepared from it. The adverse effect profile depends on the specific carrier molecule and the target tumor type. The following information is based on data from major clinical trials including the NETTER-1 trial (Lu-177 DOTATATE) and the VISION trial (Lu-177 PSMA-617).
Side Effects of Lu-177 DOTATATE Therapy (PRRT)
Very Common (more than 1 in 10 patients)
- Nausea and vomiting (especially during amino acid co-infusion)
- Fatigue and malaise
- Lymphopenia (decreased lymphocyte count)
- Thrombocytopenia (decreased platelet count)
- Anemia (decreased red blood cell count)
- Abdominal pain
Common (1 in 10 to 1 in 100 patients)
- Leukopenia (decreased white blood cell count)
- Decreased appetite
- Dizziness
- Headache
- Peripheral edema
- Elevated liver enzymes
- Injection site reactions
Uncommon (1 in 100 to 1 in 1,000 patients)
- Pancytopenia (decrease in all blood cell types)
- Renal impairment
- Secondary myelodysplastic syndrome (MDS)
- Dehydration
Rare (less than 1 in 1,000 patients)
- Acute leukemia (secondary malignancy)
- Severe hepatotoxicity (liver damage)
- Nephrotic syndrome
- Hemorrhagic complications due to severe thrombocytopenia
Side Effects of Lu-177 PSMA-617 Therapy (RLT)
Very Common (more than 1 in 10 patients)
- Fatigue
- Dry mouth (xerostomia) due to salivary gland uptake
- Nausea
- Anemia
- Thrombocytopenia
- Lymphopenia
Common (1 in 10 to 1 in 100 patients)
- Decreased appetite
- Constipation or diarrhea
- Dry eyes
- Dizziness
- Renal impairment
- Bone pain (tumor flare)
- Weight loss
Uncommon (1 in 100 to 1 in 1,000 patients)
- Pancytopenia
- Severe dry mouth requiring intervention
- Secondary myelodysplastic syndrome
Rare (less than 1 in 1,000 patients)
- Acute leukemia
- Severe renal failure
- Severe bone marrow failure
Long-Term Safety Considerations
Long-term follow-up data from clinical trials and post-marketing surveillance have identified several important safety considerations for patients receiving lutetium-177 based therapies. Bone marrow toxicity is the most common dose-limiting side effect, and recovery typically occurs between treatment cycles, although cumulative effects may be observed. Regular monitoring of complete blood counts is essential both during and after the treatment course.
Renal toxicity is a concern particularly with PRRT, where the radiolabeled peptide is filtered and reabsorbed by the proximal renal tubules. The co-infusion of positively charged amino acids (lysine and arginine) reduces the renal radiation absorbed dose by 20-40% and is standard practice during PRRT. Long-term renal function monitoring is recommended for at least 12 months after the last treatment cycle.
The risk of secondary malignancies, including myelodysplastic syndrome (MDS) and acute leukemia, has been reported in a small percentage of patients. The estimated incidence is approximately 1-2% based on available data, and the latency period is typically 2-5 years after treatment. This risk must be weighed against the significant survival benefit provided by the therapy in appropriately selected patients.
Patients who have received lutetium-177 based therapy should contact their healthcare team if they experience unexplained fever, persistent fatigue, unusual bleeding or bruising, significant decrease in urine output, or any new or worsening symptoms. Regular follow-up appointments and blood tests as scheduled by the treating team are essential for early detection of potential complications.
How Should Lutetium (177Lu) Chloride Billev Be Stored?
Storage of Lutetium (177Lu) chloride Billev is subject to strict regulatory requirements governing radioactive materials. The product must be stored in accordance with national regulations for radioactive substances and the specific storage conditions specified in the product's Summary of Product Characteristics (SmPC) or package insert.
The product should be kept in its original lead or tungsten shielded container to minimize radiation exposure to personnel and the surrounding environment. It should be stored at the temperature recommended by the manufacturer, typically at controlled room temperature (15-25 degrees Celsius) or as specified on the product label. The product should not be frozen unless specifically indicated by the manufacturer.
Storage areas for radioactive materials must be clearly designated and marked with appropriate radiation warning signs. Access to these areas must be restricted to authorized personnel. The storage area should be equipped with radiation monitoring equipment, and regular contamination surveys should be performed according to the facility's radiation protection program.
Due to the radioactive decay of lutetium-177, the product has a limited shelf life determined by its calibration date and the acceptable minimum activity level for radiolabeling. The expiry date and time printed on the label account for radioactive decay and must be strictly observed. Do not use the product after the stated expiry date.
Disposal: Any unused product or waste material contaminated with lutetium-177 must be disposed of in accordance with national and local regulations for radioactive waste. The relatively short half-life of lutetium-177 (6.647 days) means that after approximately 10 half-lives (about 67 days), the residual radioactivity will have decayed to less than 0.1% of the original level, which may allow for disposal as conventional waste depending on local regulations (decay-in-storage approach).
What Does Lutetium (177Lu) Chloride Billev Contain?
Lutetium (177Lu) chloride Billev is a sterile, clear, colorless solution containing the radioactive isotope lutetium-177 in the chemical form of lutetium chloride (LuCl₃), dissolved in dilute hydrochloric acid (HCl). The exact composition is as follows:
Active Substance
- Lutetium (177Lu) chloride — The quantity of radioactivity is expressed in gigabecquerels (GBq) at the date and time of calibration specified on the label. The actual activity at the time of use will be lower due to radioactive decay and must be calculated using standard decay correction formulas.
Excipients
- Hydrochloric acid (dilute) — Used to maintain the lutetium-177 in solution and prevent hydrolysis. The pH of the solution is typically in the range of 1-2.
- Water for injections — Serves as the solvent for the solution.
Physical Properties of Lutetium-177
| Property | Value |
|---|---|
| Atomic number | 71 |
| Physical half-life | 6.647 days |
| Decay mode | Beta-minus (β⁻) emission |
| Maximum beta energy | 498 keV |
| Mean beta energy | 134 keV |
| Principal gamma energy | 208 keV (11%), 113 keV (6.4%) |
| Maximum tissue penetration (beta) | ~2 mm |
| Daughter nuclide | Hafnium-177 (stable) |
| Production method | No-carrier-added (n.c.a.) - high specific activity |
The no-carrier-added production method is a key quality attribute of Lutetium (177Lu) chloride Billev. In this process, lutetium-177 is produced by neutron irradiation of enriched ytterbium-176 targets, followed by chemical separation of the lutetium-177 from the ytterbium target material. This results in a product with very high specific activity (radioactivity per unit mass of lutetium), which is essential for efficient radiolabeling. High specific activity ensures that a maximum number of carrier molecules can be labeled with radioactive lutetium-177, optimizing the therapeutic potential of the final product.
In contrast, carrier-added (c.a.) lutetium-177 is produced by direct neutron irradiation of lutetium-176 targets, which results in a mixture of radioactive lutetium-177 and stable (non-radioactive) lutetium. The presence of stable lutetium competes with radioactive lutetium-177 for binding sites on the carrier molecules during radiolabeling, resulting in lower labeling yields and potentially suboptimal specific activity of the final radiopharmaceutical. For this reason, no-carrier-added lutetium-177 is preferred for clinical applications requiring high specific activity.
Frequently Asked Questions About Lutetium (177Lu) Chloride Billev
Lutetium (177Lu) chloride Billev is a radiopharmaceutical precursor used for radiolabeling carrier molecules such as peptides and antibodies. These radiolabeled compounds are then used in targeted radionuclide therapy, primarily for treating neuroendocrine tumors (when labeled with DOTATATE) and metastatic castration-resistant prostate cancer (when labeled with PSMA-617). The product is not administered directly to patients but serves as a starting material for preparing therapeutic radiopharmaceuticals in nuclear medicine facilities.
Yes, Lutetium (177Lu) chloride Billev is radioactive. It contains lutetium-177, a beta-emitting radionuclide with a physical half-life of approximately 6.647 days. It must be handled exclusively by qualified personnel in authorized nuclear medicine facilities with appropriate radiation protection measures in place, following national and international regulations for radioactive materials. The radioactivity decays over time, with the product reaching negligible levels after approximately 67 days (10 half-lives).
Lutetium-177 emits beta particles that travel a short distance (approximately 2 mm maximum in tissue), delivering targeted radiation to tumor cells. When attached to carrier molecules like DOTATATE or PSMA-617, the lutetium-177 is directed specifically to cancer cells that express particular receptors. The beta radiation damages the DNA of the cancer cells, leading to cell death while minimizing damage to surrounding healthy tissue. Additionally, lutetium-177 emits low-energy gamma photons that allow imaging for treatment monitoring and dosimetry through SPECT scans.
Lutetium (177Lu) chloride Billev must only be handled by qualified professionals who are trained and authorized to work with radioactive materials in nuclear medicine facilities. This includes nuclear medicine physicians, radiopharmacists, and nuclear medicine technologists. The facility must hold appropriate licenses for handling unsealed radioactive sources. All handling must comply with national radiation protection regulations and International Atomic Energy Agency (IAEA) safety standards.
The side effects depend on the final radiolabeled product used for treatment, not the lutetium-177 chloride precursor itself. Common side effects of Lu-177 DOTATATE therapy include nausea, fatigue, bone marrow suppression (decreased blood cell counts), and abdominal pain. For Lu-177 PSMA-617 therapy, side effects include dry mouth (xerostomia), fatigue, nausea, and bone marrow suppression. Long-term risks include potential kidney toxicity and rare secondary cancers such as myelodysplastic syndrome. Most side effects are manageable and typically resolve between treatment cycles.
Lutetium-177 chloride (such as Lutetium (177Lu) chloride Billev) is the raw radiopharmaceutical precursor, a radioactive starting material that is not given to patients directly. Lutetium-177 DOTATATE (such as Lutathera) is the final radiolabeled product created by combining lutetium-177 chloride with the peptide DOTATATE through a radiolabeling process. This finished product is what is administered intravenously to patients for treating somatostatin receptor-positive neuroendocrine tumors. The precursor must undergo quality-controlled radiolabeling in a qualified radiopharmacy before it can be used for patient treatment.
References and Medical Sources
All medical claims in this article are based on peer-reviewed research, systematic reviews, randomized controlled trials, and international medical guidelines. Sources include the European Medicines Agency (EMA), International Atomic Energy Agency (IAEA), European Association of Nuclear Medicine (EANM), and major clinical trials.
- Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1). N Engl J Med. 2017;376(2):125-135. doi:10.1056/NEJMoa1607427
- Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION). N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322
- European Medicines Agency (EMA). Lutetium (177Lu) chloride - Summary of Product Characteristics. EMA Product Information. Available at: https://www.ema.europa.eu
- Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800-816. doi:10.1007/s00259-012-2330-6
- Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands. Eur J Nucl Med Mol Imaging. 2019;46(12):2536-2544. doi:10.1007/s00259-019-04485-3
- International Atomic Energy Agency (IAEA). Radiation Protection and Safety of Radiation Sources: International Basic Safety Standards. IAEA Safety Standards Series No. GSR Part 3. Vienna: IAEA; 2014.
- Kam BLR, Teunissen JJM, Krenning EP, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S103-S112. doi:10.1007/s00259-011-2039-y
- Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797-804. doi:10.1016/S0140-6736(21)00237-3
- European Pharmacopoeia. Lutetium (177Lu) solution for radiolabelling. Monograph 2798. Council of Europe, Strasbourg.
- World Health Organization (WHO). WHO Model List of Essential Medicines - 23rd List (2023). Geneva: WHO; 2023.
Medical Editorial Team
This article has been developed by the iMedic Medical Editorial Team, comprising specialists in nuclear medicine, radiopharmacy, and oncology. All content is reviewed according to international guidelines and evidence-based medicine principles.
Reviewed by board-certified specialists in nuclear medicine with expertise in targeted radionuclide therapy and radiopharmaceutical preparation.
Content based on GRADE evidence framework, drawing from randomized controlled trials, systematic reviews, and international guidelines (EMA, IAEA, EANM).
No pharmaceutical funding. All content is editorially independent, with no conflicts of interest. Updated regularly to reflect the latest clinical evidence.
This page meets WCAG 2.2 Level AAA standards. Accessible for screen readers, keyboard navigation, and high-contrast display. Supports reduced-motion preferences.